{"entity":{"id":"compugen","kind":"company","name":"Compugen","aka":["Compugen Ltd","Compugen Ltd."],"tldr":"An Israeli company that looks for new immune checkpoints in silico first and only then in the laboratory. It found PVRIG that way, and the antibody against it is in trials; its TIGIT antibody sits inside AstraZeneca's bispecific.","summary":"Compugen, listed on Nasdaq and the Tel Aviv Stock Exchange and based at 26 Harokmim Street in Holon, inverts the usual order of target discovery: it predicts candidate immune checkpoints computationally, on the platform it now calls Unigen, and validates the survivors experimentally. The approach produced PVRIG (CD112R), a receptor on T and natural killer cells that the company identified and then drugged with COM701, and its anti-TIGIT antibody COM902.\n\nThe pipeline is mostly partnered. COM701 is in trials alone and with COM902 and pembrolizumab, including a phase 1/2 study in relapsed platinum-sensitive ovarian cancer. The anti-TIGIT antibody licensed to AstraZeneca is the TIGIT arm of rilvegostomig, the PD-1 and TIGIT bispecific now in a large phase 3 programme. GS-0321, formerly COM503, is a high-affinity anti-IL-18 binding protein antibody licensed to Gilead, intended to free endogenous IL-18 inside the tumour.\n\nIt is the clearest Israeli example of the discovery-side business model: sell the target and the antibody rather than build the commercial infrastructure to sell a drug.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Compugen_(company)","links":[{"label":"Compugen","url":"https://www.cgen.com"},{"label":"SEC filer record (CIK 0001119774)","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001119774&type=20-F"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["immunotherapy","drug-discovery"],"technologies":["checkpoint-inhibitor","ai-drug-design","bispecific-antibody"],"targets":["pvrig","tigit","pd1"],"drugs":["rilvegostomig"],"companies":["astrazeneca","gilead"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06888921"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Holon","country":"IL","companyType":"biotech","website":"https://www.cgen.com","ticker":"CGEN","stage":"public","investors":[],"funding":[]},"route":"/companies/compugen/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"drug":[{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"trial":[{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/"}]}}